anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides monoclonal antibodies for human TrkB. In certain embodiments the inventive antibodies bind and activate human TrkB. In certain embodiments the inventive antibodies are selective for human TrkB in that they do not bind (or activate) human TrkA or human TrkC. In some embodiments the inventive monoclonal antibodies cross-react with murine TrkB. Humanized or veneered versions of the inventive antibodies are also encompassed. Pharmaceutical compositions that comprise inventive antibodies are provided as are methods for preparing the inventive antibodies and methods of using these for treatment, detection or purification purposes.
AIMS: One effective clinical strategy to combat obesity is intragastric botulinum toxin (BTX) injection, which increases gastric emptying time and regulates appetite. However, it remains unknown if and how BTX affects ghrelin levels.
MATERIALS AND METHODS: An obese animal model was established by feeding male mice with high-fat diet (HFD). BTX was administered by subserosal injection in the antrum via an upper midline laparotomy. The mice were monitored in terms of body weight and blood biochemical parameters. Glucose utility and insulin sensitivity were measured by intraperitoneal glucose and insulin tolerance tests. Additionally, stomach and liver were histologically examined after BTX treatment. AGS gastric adenocarcinoma cells were used to investigate the molecular mechanism by which BTX affects ghrelin expression.
KEY FINDINGS: In HFD-fed mice, BTX injection significantly decreased both food intake and body weight over a 3-week monitoring period. Moreover, HFD-induced hyperglycemia, hyperinsulinemia, dyslipidemia and obesity readouts were improved after BTX injection. Importantly, mice also exhibited decreased plasma and gastric ghrelin levels after BTX injection. In cultured AGS cells, BTX significantly increased reactive oxygen species (ROS) levels and activated nuclear factor-κB (NF-κB), which led to decreased ghrelin expression. Pre-treatment with inhibitors of either ROS or NF-κB reversed the effects of BTX on ghrelin expression in the cultured cells.
SIGNIFICANCE: BTX decreases ghrelin expression in HFD-fed animals and in AGS cells through an ROS/NF-κB-dependent pathway. This mechanism may contribute to decreased food intake in obese subjects receiving intragastric BTX injection for weight control.
In an embodiment, it is intended to provide a food or a drink for promoting hair growth and a medicinal composition for promoting hair growth which contain an extract of a plant belonging to the family Compositae or a component thereof, more specifically, a food or a drink for promoting hair growth and a medicinal composition for promoting hair growth which contain an extract of Chrysanthemum parthenium or parthenolide. In another embodiment, it is intended to provide a food or a drink for promoting hair growth and a medicinal composition for promoting hair growth which contain an extract of Chrysanthemum parthenium or parthenolide together with a member of the vitamin B family. In a still another embodiment, it is intended to provide a method of promoting hair growth, etc. by using an extract of a plant belonging to the family Compositae or a component thereof, in particular, an extract of Chrysanthemum parthenium or parthenolide. In a still another embodiment, it is intended to provide a method of promoting hair growth, etc. by using an extract of a plant belonging to the family Compositae or a component thereof, in particular, an extract of Chrysanthemum parthenium or parthenolide together with a member of the vitamin B family.
After 1 session of online simultaneous exercise training in the company of a physiotherapist via a smart phone videoconference to the VGr group, an exercise video including the exercises will be sent and the participants will be asked to do exercises 3 days a week. The cases will be asked to keep an exercise diary and the status of the diaries will be followed by calling once a week.
PROBLEM TO BE SOLVED: To obtain the subject composition optimum as a colorant for developing various colors, excellent in color development, stability and safety and improved in spread and touch, by dispersing a specific amount of gold fine particles into a prescribed metal oxide as a main component. SOLUTION: This cosmetic is obtained by dispersing 0.01-30wt.% of gold fine particles into at least one flaky metal oxide selected from the group consisting of silicon oxide, titanium oxide, aluminum oxide and zirconium oxide as a main component. The metal fine particles have preferably 1-300nm particle diameters. The flaky metal oxide has 0.1-2μm average thickness and 5-150 aspect ratio. The flaky metal oxide is preferably in an amorphous or a glassy state. The flaky metal oxide is simply and efficiently obtained, for example, by adding a gold colloid or metal compound to a solution containing an organogold compound hydrolyzable or capable of being subjected to polycondensation, coating a substrate with the solution, drying the coated film, releasing and heat-treating the dried film.
The selection of total daily doses of GSK2269557 for Part B will anticipated to be the maximum well tolerated dose selected from Part A. The subjects will receive GSK2269557 in ratio of 3:1.with placebo. If the dose selected for Part B is not well tolerated on repeat dosing the dose may be reduced during Part B or given as divided doses.
OBJECTIVE: Aim: To study the study the impact of negative factors of professional activities on the health of law enforcement officers.
PATIENTS AND METHODS: Materials and Methods: The research involved 89 law enforcement officers (58 men, and 31 women) who served for a year in practical police units after graduating from a higher educational institution. Methods: analysis and generalization of scientific and methodological literature, anthropometry, physiometry, testing, and statistical methods. The health status was assessed by body mass index, Robinson index, and vital index.
RESULTS: Results: It was found that the body mass index of law enforcement officers for one year of service in practical units deteriorated in both men and women by 1.3 kg/m2 and 0.9 kg/m2, respectively. More negative changes were observed in men. At the same time, after one year of service, the number of men with overweight (27.5 %) and even obesity of the first (13.9 %) and second (5.2 %) degrees increased significantly. In women, the changes were less pronounced. The dynamics of Robinson and vital indices, as well as the level of physical fitness, were also negative.
CONCLUSION: Conclusions: The results of the research indicate a negative impact of professional factors in terms of professional activities on the health of law enforcement officers. It has been found that adherence to the principles of a healthy lifestyle, in particular, a regimen of rationally organized motor activity, is an important area in combating the impact of negative factors of professional activities on the health of law enforcement officers.
A method is disclosed for treatment of urinary incontinence. The method includes the steps of providing to a person or animal, in the vicinity of a pubo-urethral ligament of the person or animal, a composition including collagen macromolecules that have hydroxyphenyl side groups substituted thereon, which are reacted to form dihydroxyphenyl linkages. In an embodiment, the collagen macromolecules are gelatin macromolecules. In another embodiment, the hydroxyphenyl side groups are tyramine side groups and the dihydroxyphenyl linkages are dityramine linkages. The composition can be injected into a space between a urethra and a pubis of the person or animal wherein the pubo-urethral ligament is disposed in the space. The method is advantageous, for example, based on being minimally invasive.
Techniques are described herein for collapsing clinical event data into meaningful states of patient care. In various embodiments, time-ordered streams of clinical data associated with a plurality of respective patients may be divided (402) into one or more respective pluralities of temporal segments. Each stream of clinical data may indicate a clinical history of a particular patient of the plurality of patients. Each of the one or more pluralities of temporal segments may have a different duration. In some embodiments, embedding(s) of the one or more pluralities of temporal segments into reduced dimensionality space(s) may be generated (404). Process mining may be performed (408) on the embedding(s). Based on the process mining, one or more temporal health trajectories shared among the plurality of patients may be identified (410).
Purpose: Vancomycin is commonly prescribed for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections, including patients with end stage renal disease (ESRD) receiving intermittent hemodialysis (IHD). Infection is the second-leading cause of mortality in this patient population; therefore, optimizing vancomycin dosing is essential. New guidelines recommend using the ratio of area under the curve (AUC)/minimal inhibitory concentration (MIC) dosing with a target of 400-600 to maximize efficacy and minimize vancomycin nephrotoxicity. Summary: A retrospective chart review was performed to assess the current protocol for vancomycin dosing in ESRD patients on IHD at a community hospital in North Mississippi. A protocol was developed for dosing vancomycin utilizing AUC/MIC targets in this patient population. The study included all inpatient adults with ESRD receiving IHD at least 3 times weekly and receiving vancomycin. Data collection occurred in two phases. The first phase of data collection occurred before implementation of the new protocol and assessed the current vancomycin protocol effectiveness. In phase II of data collection, an assessment of the newly developed protocol utilizing similar data collected in phase I was conducted. Conclusions: It is thought that the difference in treatment outcomes and AUC/MIC targets is due to decreased immune function in this population. For this reason, we set our goal pre-dialysis level at 20-25 mg/dL, rather than 17-25 mg/dL, which correlates with an AUC/MIC of 480-600. It is important to quickly achieve therapeutic levels for the patients that do have MRSA to improve outcomes, to sustain these levels, and to reduce adverse events and costs.
Pharmaceutical prepns. for dermatological and/or cosmetic use and which are in vesicular esp. liposomal form comprises water or lipid soluble plant ingredients and/or efficacious proteins opt. with other additives in lyotropic mesophases such as micellar systems, microemulsions, lamellar phases, hexagonal phases. USE/ADVANTAGE - The prepns. can be used skin care prods. sunscreens with UV absorbers, tanning agents, non-fatty after shaves, cleansing lotions and oils, encapsulated radical scavengers, formulations against pregnancy marks, hair and scalp care prods. bath oils, fitness frictions. They can also be used as antimycotics or agents with antimelanoma properties. The vesicular prepns. cause significant inhibition of inflammation, have increased protective and skin care effect by deep penetration into the epidermis, smooth the skin surface by occlusion formation (inhibiting the transepidermal water loss, increasing water binding in the intercellular region, increase elasticity and plasticity of the epidermis and are of excellent compatibility with the body.
The implementation "intervention", NIATx, will be deployed by the first cohort of programs in a 1-year active implementation phase. Each program is assigned an expert quality improvement coach. The coach will help the staff identify ways to improve and integrate services for individuals with co-occurring substance use and mental health disorders. Supports include an in-person coach site visit, coaching including monthly coaching calls and peer to peer coaching calls and learning sessions which promote peer-to-peer sharing about specific goals and objectives and to receive guidance on how to implement organizational level changes to improve integrated treatment services. A walk-through will allow the provider to understand the co-occurring treatment process from a customer perspective.
The active ingredient in rabeprazole sodium delayed-release capsules is rabeprazole sodium, which is a proton pump inhibitor. It is a substituted benzimidazole known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfinyl]-1H–benzimidazole sodium salt. It has an empirical formula of C18H20N3NaO3S and a molecular weight of 381.42. Rabeprazole sodium is a white to slightly yellowish-white solid. It is very soluble in water and methanol, freely soluble in ethanol, chloroform, and ethyl acetate and insoluble in ether and n-hexane. The stability of rabeprazole sodium is a function of pH; it is rapidly degraded in acid media, and is more stable under alkaline conditions. The structural figure is:

Figure 1

Rabeprazole sodium delayed-release capsules (sprinkle) are available for oral administration as 10 mg rabeprazole sodium delayed-release capsules containing enteric coated granules.

Rabeprazole sodium delayed-release capsules contain granules of rabeprazole sodium in a hard hypromellose capsule. Inactive ingredients are colloidal silicon dioxide, diacetylated monoglycerides, ethylcellulose, hydroxypropyl cellulose, hypromellose phthalate, magnesium oxide, magnesium stearate, mannitol, talc, titanium dioxide, carrageenan, potassium chloride, FD&C Yellow, No. 6 (in the 10 mg capsule), and gray printing ink.
For those subjects randomized to EXPAREL® arm - the dose of EXPAREL® will be determined by the cohort. Starting at 1mL (13.3mg) for cohort 1, the volume of EXPAREL® will be increased by 1 mL in each subsequent cohort for a maximum of 4mL (53.2mg).
AZILECT is contraindicated for use with meperidine. Serious adverse reactions have been precipitated with concomitant use of meperidine (e.g., Demerol and other tradenames) and MAO inhibitors (MAOIs) including selective MAO-B inhibitors. These adverse reactions are often described as "serotonin syndrome", a potentially serious condition, which can result in death. Typical clinical signs and symptoms include behavioral and cognitive/mental status changes (e.g., confusion, hypomania, hallucinations, agitation, delirium, headache, and coma), autonomic effects (e.g., syncope, shivering, sweating, high fever/hyperthermia, hypertension, hypotension, tachycardia, nausea, diarrhea), and somatic effects (e.g., muscular rigidity, myoclonus, muscle twitching, hyperreflexia manifested by clonus, and tremor). At least 14 days should elapse between discontinuation of AZILECT and initiation of treatment with meperidine.  
For similar reasons, AZILECT should not be administered with the analgesic agents tramadol, methadone, and propoxyphene.  
In the post-marketing period, serotonin syndrome has been reported in a patient erroneously treated with a higher than recommended dose of AZILECT (4 mg daily) and tramadol.
BACKGROUND: From an individual's perspective, social frailty may act as a key determinant of social capital, which is essential for meeting social needs and improvement of overall wellbeing. The present study aimed to understand the social frailty and its determining factors among Indian older adults.
METHODS: Data from the Longitudinal Ageing Study in India (LASI)-wave 1 was used. For the assessment of social frailty the study proposed a multidimensional Social Frailty Index (SFI) score ranging between 0 and 100 using 17 indicators. Bivariate analysis and quantile regression models were applied.
RESULTS: The study results indicated that on average female older adults (mean SFI = 63.7) are relatively more socially frail than male older adults (mean SFI = 59.0). Further, the quantile regression analysis revealed that at the 10th, 25th, 50th, and 75th percentiles, female older adults were significantly more likely to be socially frail than male older adults (β = 3.80, p < .01; β = 2.82, p < .01; β = 1.72, p < .01; and β = 2.62, p < .01, respectively). Educational attainment and better economic condition showed a protective effect against social frailty.
CONCLUSIONS: Investment to improve geriatric health status and socioeconomic conditions shall be a key focus to reduce social frailty prevalence among the older adults. A specific consideration is needed for addressing social frailty among female older adults.
A cardiac health assessment system includes a memory, a circuit board, and a touchscreen controller integrated into a handheld electronic device (HED). The memory stores a classification model, a regression model, and instructions about a cardiac monitoring application. The circuit board includes a microphonic sensor, an Inertial Measurement Unit (IMU) sensor, a camera sensor, and a processor. The microphonic sensor captures cardiac sound wave signals indicative of the cardiac health of a user. The IMU sensor captures seismic signals indicative of the cardiac health of the user. The camera sensor enables visual data collection of tissue and photoplethysmography. The processor is configured to: execute the instructions, display commands to position the HED against the chest of the user, detect abnormal heart activity by deploying the classification model, and estimate intracardiac pressure by deploying the regression model. The touchscreen controller displays cardiac diagnostic information.
Chordoma is an uncommon (400 case/year in the U.S.) and potentially fatal bone tumor derived from remnants of embryonic notochord. It occurs primarily in the axial skeleton and has a mean age at diagnosis of 55 years, with a range from early childhood to over 70 years. This tumor usually presents at an advanced stage and the associated mortality is high due to local destruction and distant metastases. Chordoma is rare in African-Americans and is typically sporadic; there are few reports of these tumors arising congenitally or within members of the same family.

In 1996, we have identified and studied one large family in which 8 relatives in three generations have chordoma; the inheritance pattern suggests transmission of a mutation in an autosomal dominant gene. Using information from this family, we tentatively mapped this gene to the long arm of chromosome 7. To confirm this finding, and to fine map and clone the gene, we needed to study additional chordoma families.

In an effort to identify such families, we have developed collaborations with four SEER registries covering the populations of Detroit, Los Angeles, Iowa, and New Mexico. Each registry will identify all chordoma cases diagnosed since 1988 and invite them (or the next of kin of deceased cases) to participate in our study. Through 1997, the registries have identified a total of 140 chordoma cases, 96 of whom are living. The registries will invite these patients (or their next of kin) to participate in the study. The study components included completion of a self-administered personal and family medical history questionnaire, retrieval of medical records and pathology reports pertaining to chordoma, and collection of paraffin-embedded chordoma tissue and buccal mucosal cells for genetic studies. NCI carried out all the data collection activities for the study subjects identified through the Detroit registry. NCI also conducted the buccal cell collection component of the study for all patients identified by the other three registries. These three registries will carry out all other study activities on these patients/next of kin and sent the data and slides prepared from the paraffin blocks to NCI. NCI will analyze the questionnaire data to determine if any unusual patterns of cancers other than chordoma or other medical conditions appear to cluster in families of the chordoma patients. Selected members of any families with two or more relatives with chordoma will be invited to participate in a separate clinical and molecular study conducted at NIH to try to identify the chordoma gene. DNA from the buccal cells and tumor blocks from all other patients with 'sporadic' chordoma identified through the registries (likely to comprise most patients) will not be studied until we or others have identified such a gene.
Patients receive systemic treatment with tocilizumab IV over 60 minutes with or without atezolizumab IV over 30-60 minutes on day 1. Within 3-7 days, patients undergo FSRT for 3 fractions over 3-5 days in the absence of disease progression or unacceptable toxicity. Starting 4 weeks from the first dose of systemic treatment, patients resume treatment with tocilizumab with or without atezolizumab. Treatment repeats every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI throughout the trial.
Blast wave exposure, a leading cause of hearing loss and balance dysfunction among military personnel, arises primarily from direct mechanical damage to the mechanosensory hair cells and supporting structures or indirectly through excessive oxidative stress. We previously reported that HK-2, an orally active, multifunctional redox modulator (MFRM), was highly effective in reducing both hearing loss and hair cells loss in rats exposed to a moderate intensity workday noise that likely damages the cochlea primarily from oxidative stress versus direct mechanical trauma. To determine if HK-2 could also protect cochlear and vestibular cells from damage caused primarily from direct blast-induced mechanical trauma versus oxidative stress, we exposed rats to six blasts of 186 dB peak SPL. The rats were divided into four groups: (B) blast alone, (BEP) blast plus earplugs, (BHK-2) blast plus HK-2 and (BEPHK-2) blast plus earplugs plus HK-2. HK-2 was orally administered at 50 mg/kg/d from 7-days before to 30-day after the blast exposure. Cochlear and vestibular tissues were harvested 60-d post-exposure and evaluated for loss of outer hair cells (OHC), inner hair cells (IHC), auditory nerve fibers (ANF), spiral ganglion neurons (SGN) and vestibular hair cells in the saccule, utricle and semicircular canals. In the untreated blast-exposed group (B), massive losses occurred to OHC, IHC, ANF, SGN and only the vestibular hair cells in the striola region of the saccule. In contrast, rats treated with HK-2 (BHK-2) sustained significantly less OHC (67%) and IHC (57%) loss compared to the B group. OHC and IHC losses were smallest in the BEPHK-2 group, but not significantly different from the BEP group indicating lack of protective synergy between EP and HK-2. There was no loss of ANF, SGN or saccular hair cells in the BHK-2, BEP and BEPHK-2 groups. Thus, HK-2 not only significantly reduced OHC and IHC damage, but completely prevented loss of ANF, SGN and saccule hair cells. The powerful protective effects of this oral MFRM make HK-2 an extremely promising candidate for human clinical trials.
Subjects above 60 years of age received 1 dose of Fluarix/Influsplit SSW 2012-2013 vaccine at Day 0. The vaccine was administered intramuscularly in the deltoid of the non-dominant arm.
Three doses of pSG2.HIVconsv DNA followed by boost with high dose ChAdV63.HIVconsv followed by boost with MVA.HIVconsv at week 0,4,8,12 and 20, respectively (n=8). Followed up at 6, 12 and 24 months after last vaccination.
A single dose of Satoreotide trizoxetan will be administered as a slow intravenous (i.v.) bolus injected over 1 minute at Baseline/Day 1.